Literature DB >> 26558820

Leukotriene B4 Activates Pulmonary Artery Adventitial Fibroblasts in Pulmonary Hypertension.

Jin Qian1,2, Wen Tian1,2, Xinguo Jiang1,2, Rasa Tamosiuniene1,2, Yon K Sung1,2, Eric M Shuffle1,2, Allen B Tu1,2, Antonia Valenzuela2, Shirley Jiang2, Roham T Zamanian2, David F Fiorentino2, Norbert F Voelkel3, Marc Peters-Golden4, Kurt R Stenmark5, Lorinda Chung2, Marlene Rabinovitch2, Mark R Nicolls1,2.   

Abstract

A recent study demonstrated a significant role for leukotriene B4 (LTB4) causing pulmonary vascular remodeling in pulmonary arterial hypertension. LTB4 was found to directly injure luminal endothelial cells and promote growth of the smooth muscle cell layer of pulmonary arterioles. The purpose of this study was to determine the effects of LTB4 on the pulmonary adventitial layer, largely composed of fibroblasts. Here, we demonstrate that LTB4 enhanced human pulmonary artery adventitial fibroblast proliferation, migration, and differentiation in a dose-dependent manner through its cognate G-protein-coupled receptor, BLT1. LTB4 activated human pulmonary artery adventitial fibroblast by upregulating p38 mitogen-activated protein kinase as well as Nox4-signaling pathways. In an autoimmune model of pulmonary hypertension, inhibition of these pathways blocked perivascular inflammation, decreased Nox4 expression, reduced reactive oxygen species production, reversed arteriolar adventitial fibroblast activation, and attenuated pulmonary hypertension development. This study uncovers a novel mechanism by which LTB4 further promotes pulmonary arterial hypertension pathogenesis, beyond its established effects on endothelial and smooth muscle cells, by activating adventitial fibroblasts.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  NADPH oxidase; fibroblasts; inflammation; leukotriene B4; p38 mitogen-activated protein kinases; pulmonary artery; vascular remodeling

Mesh:

Substances:

Year:  2015        PMID: 26558820      PMCID: PMC4646718          DOI: 10.1161/HYPERTENSIONAHA.115.06370

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  66 in total

Review 1.  Epidemiology and risk factors for pulmonary hypertension in systemic sclerosis.

Authors:  Aaliya Yaqub; Lorinda Chung
Journal:  Curr Rheumatol Rep       Date:  2013-01       Impact factor: 4.592

2.  Nitric oxide reduces NADPH oxidase 5 (Nox5) activity by reversible S-nitrosylation.

Authors:  Jin Qian; Feng Chen; Yevgeniy Kovalenkov; Deepesh Pandey; M Arthur Moseley; Matthew W Foster; Stephen M Black; Richard C Venema; David W Stepp; David J R Fulton
Journal:  Free Radic Biol Med       Date:  2012-03-01       Impact factor: 7.376

3.  Inhibition of p38 pathway leads to OA-like changes in a rat animal model.

Authors:  Indira Prasadam; Xinzhan Mao; Yanping Wang; Wei Shi; Ross Crawford; Yin Xiao
Journal:  Rheumatology (Oxford)       Date:  2012-01-12       Impact factor: 7.580

4.  Chronic hypoxia induces constitutive p38 mitogen-activated protein kinase activity that correlates with enhanced cellular proliferation in fibroblasts from rat pulmonary but not systemic arteries.

Authors:  D J Welsh; A J Peacock; M MacLean; M Harnett
Journal:  Am J Respir Crit Care Med       Date:  2001-07-15       Impact factor: 21.405

5.  Pyridinylimidazole compound SB 203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase.

Authors:  S Kumar; M S Jiang; J L Adams; J C Lee
Journal:  Biochem Biophys Res Commun       Date:  1999-10-05       Impact factor: 3.575

Review 6.  Molecular characterization of reactive oxygen species in systemic and pulmonary hypertension.

Authors:  Li Zuo; Bradley A Rose; William J Roberts; Feng He; Amy K Banes-Berceli
Journal:  Am J Hypertens       Date:  2014-02-19       Impact factor: 2.689

Review 7.  Nox proteins in signal transduction.

Authors:  David I Brown; Kathy K Griendling
Journal:  Free Radic Biol Med       Date:  2009-07-21       Impact factor: 7.376

8.  Hypoxia exposure induces the emergence of fibroblasts lacking replication repressor signals of PKCzeta in the pulmonary artery adventitia.

Authors:  Mita Das; Nana Burns; Shelly J Wilson; Wojciech M Zawada; Kurt R Stenmark
Journal:  Cardiovasc Res       Date:  2008-01-24       Impact factor: 10.787

9.  Fluvastatin inhibits hypoxic proliferation and p38 MAPK activity in pulmonary artery fibroblasts.

Authors:  Christopher M Carlin; Andrew J Peacock; David J Welsh
Journal:  Am J Respir Cell Mol Biol       Date:  2007-06-07       Impact factor: 6.914

Review 10.  Role of reactive oxygen species in chronic hypoxia-induced pulmonary hypertension and vascular remodeling.

Authors:  Eva Nozik-Grayck; Kurt R Stenmark
Journal:  Adv Exp Med Biol       Date:  2007       Impact factor: 2.622

View more
  29 in total

1.  The Roles of Immunity in the Prevention and Evolution of Pulmonary Arterial Hypertension.

Authors:  Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Respir Crit Care Med       Date:  2017-05-15       Impact factor: 21.405

2.  Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation.

Authors:  Wen Tian; Xinguo Jiang; Yon K Sung; Eric Shuffle; Ting-Hsuan Wu; Peter N Kao; Allen B Tu; Peter Dorfmüller; Aiqin Cao; Lingli Wang; Gongyong Peng; Yesl Kim; Patrick Zhang; James Chappell; Shravani Pasupneti; Petra Dahms; Peter Maguire; Hassan Chaib; Roham Zamanian; Marc Peters-Golden; Michael P Snyder; Norbert F Voelkel; Marc Humbert; Marlene Rabinovitch; Mark R Nicolls
Journal:  Circulation       Date:  2019-08-29       Impact factor: 29.690

Review 3.  Update in Pulmonary Vascular Disease 2015.

Authors:  Bradley A Maron; Mark T Gladwin; Marc A Simon
Journal:  Am J Respir Crit Care Med       Date:  2016-06-15       Impact factor: 21.405

Review 4.  Vascular Metabolic Mechanisms of Pulmonary Hypertension.

Authors:  Xiao-Fan Shi; Yun-Chao Su
Journal:  Curr Med Sci       Date:  2020-07-17

Review 5.  GPCRs in pulmonary arterial hypertension: tipping the balance.

Authors:  Jean Iyinikkel; Fiona Murray
Journal:  Br J Pharmacol       Date:  2018-04-17       Impact factor: 8.739

6.  Dominant Role for Regulatory T Cells in Protecting Females Against Pulmonary Hypertension.

Authors:  Rasa Tamosiuniene; Olga Manouvakhova; Paul Mesange; Toshie Saito; Jin Qian; Mrinmoy Sanyal; Yu-Chun Lin; Linh P Nguyen; Amir Luria; Allen B Tu; Joshua M Sante; Marlene Rabinovitch; Desmond J Fitzgerald; Brian B Graham; Aida Habtezion; Norbert F Voelkel; Laure Aurelian; Mark R Nicolls
Journal:  Circ Res       Date:  2018-03-15       Impact factor: 17.367

Review 7.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14

Review 8.  Challenges and opportunities in treating inflammation associated with pulmonary hypertension.

Authors:  Norbert F Voelkel; Rasa Tamosiuniene; Mark R Nicolls
Journal:  Expert Rev Cardiovasc Ther       Date:  2016-05-04

Review 9.  Role of oxidized lipids in pulmonary arterial hypertension.

Authors:  Salil Sharma; Grégoire Ruffenach; Soban Umar; Negar Motayagheni; Srinivasa T Reddy; Mansoureh Eghbali
Journal:  Pulm Circ       Date:  2016-09       Impact factor: 3.017

Review 10.  Emerging therapeutics in pulmonary hypertension.

Authors:  Matthew K Hensley; Andrea Levine; Mark T Gladwin; Yen-Chun Lai
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-02-01       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.